155 related articles for article (PubMed ID: 12482659)
41. High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility.
Goetschius DJ; Hartmann SR; Subramanian S; Bator CM; Christensen ND; Hafenstein SL
Sci Rep; 2021 Feb; 11(1):3498. PubMed ID: 33568731
[TBL] [Abstract][Full Text] [Related]
42. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
[TBL] [Abstract][Full Text] [Related]
43. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
44. The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network.
DiGiuseppe S; Bienkowska-Haba M; Hilbig L; Sapp M
Virology; 2014 Jun; 458-459():93-105. PubMed ID: 24928042
[TBL] [Abstract][Full Text] [Related]
45. Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions.
Kondo K; Ishii Y; Mori S; Shimabukuro S; Yoshikawa H; Kanda T
Virology; 2009 Nov; 394(2):259-65. PubMed ID: 19766281
[TBL] [Abstract][Full Text] [Related]
46. Direct binding of retromer to human papillomavirus type 16 minor capsid protein L2 mediates endosome exit during viral infection.
Popa A; Zhang W; Harrison MS; Goodner K; Kazakov T; Goodwin EC; Lipovsky A; Burd CG; DiMaio D
PLoS Pathog; 2015 Feb; 11(2):e1004699. PubMed ID: 25693203
[TBL] [Abstract][Full Text] [Related]
47. Human papillomavirus 16 L2 inhibits the transcriptional activation function, but not the DNA replication function, of HPV-16 E2.
Okoye A; Cordano P; Taylor ER; Morgan IM; Everett R; Campo MS
Virus Res; 2005 Mar; 108(1-2):1-14. PubMed ID: 15681049
[TBL] [Abstract][Full Text] [Related]
48. Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism.
Day PM; Thompson CD; Lowy DR; Schiller JT
J Virol; 2017 May; 91(10):. PubMed ID: 28250129
[TBL] [Abstract][Full Text] [Related]
49. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.
Day PM; Baker CC; Lowy DR; Schiller JT
Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14252-7. PubMed ID: 15383670
[TBL] [Abstract][Full Text] [Related]
50. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
51. Baculovirus expression of the human papillomavirus type 16 capsid proteins: detection of L1-L2 protein complexes.
Xi SZ; Banks LM
J Gen Virol; 1991 Dec; 72 ( Pt 12)():2981-8. PubMed ID: 1662690
[TBL] [Abstract][Full Text] [Related]
52. Nuclear import strategies of high risk HPV16 L1 major capsid protein.
Nelson LM; Rose RC; Moroianu J
J Biol Chem; 2002 Jun; 277(26):23958-64. PubMed ID: 11971900
[TBL] [Abstract][Full Text] [Related]
53. Infectious human papillomavirus type 18 pseudovirions.
Stauffer Y; Raj K; Masternak K; Beard P
J Mol Biol; 1998 Oct; 283(3):529-36. PubMed ID: 9784363
[TBL] [Abstract][Full Text] [Related]
54. Novel cellular interacting partners of the human papillomavirus 16 transcription/replication factor E2.
Boner W; Morgan IM
Virus Res; 2002 Dec; 90(1-2):113-8. PubMed ID: 12457967
[TBL] [Abstract][Full Text] [Related]
55. Interaction of the HPV E7 proteins with the pCAF acetyltransferase.
Avvakumov N; Torchia J; Mymryk JS
Oncogene; 2003 Jun; 22(25):3833-41. PubMed ID: 12813456
[TBL] [Abstract][Full Text] [Related]
56. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
57. Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
Day PM; Thompson CD; Schowalter RM; Lowy DR; Schiller JT
J Virol; 2013 Apr; 87(7):3862-70. PubMed ID: 23345514
[TBL] [Abstract][Full Text] [Related]
58. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
59. The papillomavirus major capsid protein L1.
Buck CB; Day PM; Trus BL
Virology; 2013 Oct; 445(1-2):169-74. PubMed ID: 23800545
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.
Sasagawa T; Pushko P; Steers G; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L; Tommasino M
Virology; 1995 Jan; 206(1):126-35. PubMed ID: 7831768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
